• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by MetLife Inc.

    11/1/24 5:05:26 PM ET
    $MET
    Life Insurance
    Finance
    Get the next $MET alert in real time by email
    SC 13D/A 1 d873205dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    AMENDMENT NO. 99 TO

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

     

    MetLife, Inc.

    (Name of Issuer)

    Common Stock, par value $.01 per share

    (Title of Class of Securities)

    59156R108

    (CUSIP Number)

    Monica M. Curtis

    Executive Vice President and Chief Legal Officer

    MetLife, Inc.

    200 Park Avenue

    New York, NY 10166-0188

    (212) 578-9500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    November 1, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

      •  

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 2 of 9 Pages 

     

     (1)   

    Names of Reporting Persons         Board of Directors of MetLife, Inc., as an entity

     

    I.R.S. Identification

    Nos. of Above Persons             Not applicable

     (2)  

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     (3)  

    SEC Use Only

     

     (4)  

    Source of Funds

     

     Not Applicable. See Item 4.

     (5)  

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

    Citizenship or Place of Organization

     

     U.S.A.

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

        (7)    

    Sole Voting Power

     

     0

        (8)   

    Shared Voting Power

     

    112,294,326*

        (9)   

    Sole Dispositive Power

     

     0

       (10)   

    Shared Dispositive Power

     

     0

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    112,294,326*

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

     ☐

    (13)  

    Percent of Class Represented by Amount in Row 11

     

    16.2%

    (14)  

    Type of Reporting Person

     

     IC

     

    *

    Unless otherwise indicated, all information relating to beneficial ownership of the Shares by the Reporting Persons is as of October 28, 2024.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 3 of 9 Pages

    Items 4 and 5 are amended and restated as set forth below:

    ITEM 4. PURPOSE OF TRANSACTION.

    The Board of Directors (the “Board”) is reporting beneficial ownership of 112,294,326 shares of Common Stock (the “Shares”) held by the MetLife Policyholder Trust (the “Trust”) under the Plan of Reorganization, dated September 28, 1999, as amended (the “Plan”), of Metropolitan Life Insurance Company (“MetLife”).

    On April 7, 2000, 494,466,664 Shares were issued to the Trust pursuant to Section 5.2(d) of the Plan, a copy of which is attached as an exhibit to this statement. No consideration has been separately provided therefor by any member of the Board, except for Shares allocated to such member pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries (i) under the Purchase and Sale Program provided for by the Trust Agreement (as defined below), (ii) pursuant to the Issuer’s split-off of Reinsurance Group of America, Incorporated, in September 2008, and (iii) to withdraw Shares from the Trust, as well as escheatment of unclaimed Shares, have resulted in a decrease in the number of Shares held by the Trust from 494,466,664
    to 112,294,326 (as adjusted to reflect refinements in the calculation of the number of Shares issued to the Trust under the Plan).

    Under the Plan and the MetLife Policyholder Trust Agreement, dated as of November 3, 1999 (as amended, the “Trust Agreement”), by and among MetLife, the Issuer, Wilmington Trust Company (the “Trustee”) and ChaseMellon Shareholder Services, L.L.C., as custodian (now known as Computershare Inc., the “Custodian”), a copy of which is attached as an exhibit to this statement, certain eligible policyholders of MetLife (“Trust Eligible Policyholders”) have been allocated a number of interests in the Trust (“Trust Interests”) equal to the number of shares of Common Stock allocated to the Trust Eligible Policyholders in accordance with the Plan. The assets of the Trust principally are the Shares issued to the Trust for the benefit of the Trust Eligible Policyholders and permitted transferees (collectively, the “Beneficiaries”). The Shares are held in the name of the Trustee, on behalf of the Trust, which has legal title over the Shares. The Beneficiaries do not have legal title to any part of the assets of the Trust. The Trust Interests represent undivided fractional interests in the Shares and other assets of the Trust beneficially owned by a Trust Beneficiary through the Custodian.

    The Trust Agreement provides the Trustee with directions as to the manner in which to vote, assent or consent the Shares at all times during the term of the Trust. On all matters brought for a vote before the stockholders of the Issuer, with the exception of a Beneficiary Consent Matter (as defined below), the Trustee will vote in accordance with the recommendation given by the Board of the Issuer to its stockholders or, if no such recommendation is given, as directed by the Board. On all Beneficiary Consent Matters, the Trustee will vote all of the Shares in favor of, in opposition to or abstain from the matter in the same ratio as the Trust Interests of the Beneficiaries that returned voting instructions to the Trustee indicated preferences for voting in favor of, in opposition to or abstaining from such matter. The Trust Agreement also contains provisions allowing Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares to participate in any tender or exchange offer for the Common Stock and to make any cash or share election, or perfect any dissenter’s rights, in connection with a merger of the Issuer.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 4 of 9 Pages

    A “Beneficiary Consent Matter” is:

     

      (i)

    a contested election of directors or, subject to certain conditions, the removal of a director,

     

      (ii)

    a merger or consolidation, a sale, lease or exchange of all or substantially all of the assets or a recapitalization or dissolution of the Issuer, if it requires a vote of stockholders under applicable Delaware law,

     

      (iii)

    any transaction that would result in an exchange or conversion of the Shares for cash, securities or other property,

     

      (iv)

    issuances of Common Stock prior to the first anniversary of the effective date of the Plan (the “Effective Date”) at a price materially below the prevailing market price, if a vote is required to approve the issuance under Delaware law, other than issuances in an underwritten public offering or pursuant to an employee benefit plan,

     

      (v)

    before the first anniversary of the Effective Date, any matter that requires approval by a vote of more than a majority of the outstanding stock of the Issuer entitled to vote thereon under Delaware law or the certificate of incorporation or the by-laws of the Issuer, and any amendment to the certificate of incorporation or by-laws of the Issuer that is submitted to a vote of stockholders for approval, and

     

      (vi)

    proposals submitted to stockholders requiring the Board to amend the Issuer’s stockholder rights plan, or redeem rights under that plan, other than a proposal with respect to which the Issuer has received advice of nationally-recognized legal counsel to the effect that the proposal is not a proper subject for stockholder action under Delaware law. The Issuer does not currently have a stockholder rights plan.

    The Trust Agreement contains provisions enabling the Beneficiaries to withdraw the Shares allocated to them under the Plan and the Trust Agreement for resale or otherwise and to receive dividends on such Shares.


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 5 of 9 Pages

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

     

    (a)

    As an entity, the Board of the Issuer beneficially owns 112,294,326 shares, or 16.2% of the Issuer’s outstanding Common Stock. The Board of the Issuer is deemed to beneficially own the shares of Common Stock held by the Trust because the Board will direct the voting of these shares on certain matters submitted to a vote of stockholders. See Item 4.

     

    (b)

    As an entity, the Board of the Issuer has shared voting power with respect to 112,294,326 shares of Common Stock.

     

    (c)

    There were no transactions in the class of securities reported on that were effected by the Reporting Persons since July 26, 2024 other than transactions described in Item 4 which resulted in a decrease in the number of shares of Common Stock held by the Trust from 113,929,100 to 112,294,326.

     

    (d)

    The Beneficiaries of the Trust have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares allocated to them under the Plan and the Trust Agreement. See Item 4.

    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

    Exhibit 99.1 Joint Filing Agreement under Rule 13d-1(k)(1)


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 6 of 9 Pages

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

    Dated: November 1, 2024

     

    *

    Cheryl W. Grisé

        

    *

    Carlos M. Gutierrez

        

    *

    Carla A. Harris

        

    *

    Laura J. Hay

        

    *

    David L. Herzog

        

    *

    R. Glenn Hubbard

        

    *

    Jeh C. Johnson

        

    *

    Edward J. Kelly, III

        

    *

    William E. Kennard

        

    *

    Michel A. Khalaf

        

    *

    Diana L. McKenzie

        

    *

    Denise M. Morrison

        

    *

    Mark A. Weinberger

        


    SCHEDULE 13D

     

    CUSIP No. 59156R108   Page 7 of 9 Pages

     

           * By    /s/ John A. Hall
        John A. Hall
        Attorney-in-fact
    Get the next $MET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MET

    DatePrice TargetRatingAnalyst
    1/6/2026$97.00Outperform → In-line
    Evercore ISI
    12/16/2025$101.00Outperform
    Mizuho
    9/19/2025$84.00Overweight → Neutral
    Piper Sandler
    9/16/2025$95.00Outperform
    Wolfe Research
    1/23/2025$97.00Market Perform
    BMO Capital Markets
    10/9/2024$97.00Buy
    TD Cowen
    9/5/2024$91.00Overweight
    Barclays
    1/8/2024$80.00Neutral → Buy
    Goldman
    More analyst ratings

    $MET
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AM Best Assigns Issue Credit Rating to MetLife, Inc.'s New Subordinated Debentures

    AM Best has assigned a Long-Term Issue Credit Rating of "bbb+" (Good) to the newly issued $1 billion, 5.85% subordinated debentures, due March 15, 2056, issued by MetLife, Inc. (MetLife) (headquartered in New York, NY) (NYSE:MET). The outlook assigned to this Credit Rating (rating) is stable. All other ratings of MetLife and its subsidiaries remain unchanged. The proceeds from this debt issuance are expected to be used to cover general business purposes. MetLife's proforma adjusted financial leverage and the historical interest coverage are in line with its current ratings, and its holding company liquidity is strong. This press release relates to Credit Ratings that have been published

    2/26/26 5:42:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Appoints Two Experienced Leaders to Board of Directors

    MetLife, Inc. (NYSE:MET) today announced that Dan Glaser and Michelle Seitz were elected to its Board of Directors (the "Board"), effective immediately. Both leaders bring significant leadership and business experience to their roles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224365562/en/MetLife today announced that Dan Glaser and Michelle Seitz were elected to its Board of Directors, effective immediately. Glaser, currently an operating partner at the private investment firm CD&R, has held senior positions in commercial insurance and insurance brokerage for more than 40 years, including serving for a decade as presiden

    2/24/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Executive to Speak at Raymond James 47th Annual Institutional Investors Conference

    MetLife, Inc. (NYSE:MET) today announced that Ramy Tadros, regional president of MetLife's U.S. Business and head of MetLife Holdings, will participate in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on Wednesday, March 4, 2026, beginning at 10:25 a.m. (ET). A live webcast of the presentation will be available over the internet at https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/fnXahDQq5cAwNB3QpWHPxq. Those who want to listen should go to the website at least 15 minutes prior to the presentation to download and install any necessary software. A replay of the presentation will be available until Wednesday, March 11, 2026, at 11:59 p.m. (ET) a

    2/18/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, U.S. Business Tadros Ramy was granted 42,916 shares and covered exercise/tax liability with 2,299 shares, increasing direct ownership by 22% to 221,985 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    2/26/26 4:36:42 PM ET
    $MET
    Life Insurance
    Finance

    Director Seitz Michelle was granted 273 units of Common Stock (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    2/26/26 4:36:36 PM ET
    $MET
    Life Insurance
    Finance

    EVP & Chief Risk Officer Debel Marlene covered exercise/tax liability with 5,624 shares and was granted 30,002 shares, increasing direct ownership by 18% to 158,513 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    2/26/26 4:36:30 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MET
    SEC Filings

    View All

    Johnson Jeh C. bought $879 worth of shares (17 units at $51.69) and was granted 19 shares, increasing direct ownership by 1% to 2,545 units (SEC Form 4)

    4 - METLIFE INC (0001099219) (Issuer)

    12/18/23 5:20:05 PM ET
    $MET
    Life Insurance
    Finance

    MetLife downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded MetLife from Outperform to In-line and set a new price target of $97.00

    1/6/26 8:46:59 AM ET
    $MET
    Life Insurance
    Finance

    Mizuho initiated coverage on MetLife with a new price target

    Mizuho initiated coverage of MetLife with a rating of Outperform and set a new price target of $101.00

    12/16/25 8:59:16 AM ET
    $MET
    Life Insurance
    Finance

    MetLife downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded MetLife from Overweight to Neutral and set a new price target of $84.00

    9/19/25 8:25:43 AM ET
    $MET
    Life Insurance
    Finance

    SEC Form 8-K filed by MetLife Inc.

    8-K - METLIFE INC (0001099219) (Filer)

    2/26/26 4:12:16 PM ET
    $MET
    Life Insurance
    Finance

    SEC Form FWP filed by MetLife Inc.

    FWP - METLIFE INC (0001099219) (Subject)

    2/24/26 4:46:23 PM ET
    $MET
    Life Insurance
    Finance

    SEC Form 8-K filed by MetLife Inc.

    8-K - METLIFE INC (0001099219) (Filer)

    2/24/26 4:21:13 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Leadership Updates

    Live Leadership Updates

    View All

    MetLife Appoints Two Experienced Leaders to Board of Directors

    MetLife, Inc. (NYSE:MET) today announced that Dan Glaser and Michelle Seitz were elected to its Board of Directors (the "Board"), effective immediately. Both leaders bring significant leadership and business experience to their roles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224365562/en/MetLife today announced that Dan Glaser and Michelle Seitz were elected to its Board of Directors, effective immediately. Glaser, currently an operating partner at the private investment firm CD&R, has held senior positions in commercial insurance and insurance brokerage for more than 40 years, including serving for a decade as presiden

    2/24/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Investment Management Completes Acquisition of PineBridge Investments

    The combination brings together global scale and deep specialization, accelerating MetLife's growth in asset management MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), closed today on its acquisition of PineBridge Investments (PineBridge). The combined business manages $734.7 billion1 of assets, serving clients around the world. Accelerating growth in asset management is a top priority for MetLife in its New Frontier strategy. The acquisition brings together MIM's institutional strength and scale with PineBridge's global footprint and deep specialization to position MIM as a top-tier diversified global asset manager. "Toget

    12/30/25 5:15:00 AM ET
    $MET
    Life Insurance
    Finance

    MetLife and Global Citizen Announce Major Partnership to Drive Economic Change and Foster Resilient Communities

    MetLife Foundation Commits $9 Million to FIFA Global Citizen Education Fund Today at the 2025 Global Citizen Festival, MetLife, a leading financial services company providing insurance and employee benefits, proudly announced becoming a major partner with Global Citizen, the world's largest movement to end extreme poverty, with a new three-year partnership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250926660696/en/NEW YORK, NEW YORK - SEPTEMBER 27: (L-R) Michael Roberts and Nuria Garcia speak onstage during the 2025 Global Citizen Festival at Central Park on September 27, 2025 in New York City. (Photo by Noam Galai/Getty

    9/27/25 9:15:00 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Financials

    Live finance-specific insights

    View All

    MetLife Announces First Quarter 2026 Preferred Stock Dividend Actions

    Declares Series D, E and F Preferred Stock Dividends Declares Series A Preferred Stock Dividend, Subject to Final Confirmation MetLife, Inc. (NYSE:MET) today announced that it has declared the following preferred stock dividends: Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of wh

    2/17/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife Announces Full Year and 4Q 2025 Results

    MetLife, Inc. (NYSE:MET) today announced its full year and fourth quarter 2025 results. Earnings   Return   Per Share on Equity (ROE     4Q 2025   4Q 2025 Net Income $1.17 ROE 12.0%   Adjusted Earnings $2.49 Adjusted ROE 17.6% Full Year Results Net income was $3.2 billion, or $4.71 per share. Adjusted earnings per share, excluding total notable items, up 10%1 to $8.89. Premiums, fees and other revenues (PFOs) increased 10% to $57.6 billion. Adjusted PFOs, excluding pension risk transfers (PRT), were up 5% to $49.8 billion. RIS record sales,

    2/4/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    MetLife CFO John McCallion Provides Fourth Quarter and Full Year 2025 Financial Update Video

    MetLife, Inc. (NYSE:MET) today announced that John McCallion, executive vice president and chief financial officer, and head of MetLife Investment Management, has provided a fourth quarter and full year 2025 financial update video. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204908797/en/ The video can be viewed on the company's website at https://www.metlife.com/about-us/newsroom/#video. About MetLife MetLife, Inc. (NYSE:MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help in

    2/4/26 4:15:00 PM ET
    $MET
    Life Insurance
    Finance

    $MET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MetLife Inc.

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    11/1/24 5:05:26 PM ET
    $MET
    Life Insurance
    Finance

    Amendment: SEC Form SC 13D/A filed by MetLife Inc.

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    8/1/24 4:38:49 PM ET
    $MET
    Life Insurance
    Finance

    SEC Form SC 13D/A filed by MetLife Inc. (Amendment)

    SC 13D/A - METLIFE INC (0001099219) (Subject)

    5/2/24 5:34:57 PM ET
    $MET
    Life Insurance
    Finance